Generics drive Amerisource financials; Facilities planned, completed and approved;

> Big 3 drug distributor Amerisource cites sales of generics as a driver in its higher-than-expected quarterly profit growth. Article

> The FDA has approved Orthovita's facility in Malvern, PA, for collagen processing and the manufacture of collagen-based products. Article

> Novavax has been issued U.S. Patent No. 7,763,450, "Functional Influenza Virus-Like Particles (VLPS)," for the manufacturing process that uses influenza gene sequences for production of vaccines to protect against current and future seasonal and pandemic flu strains. Release

> Meridian Life Science is boosting investment in facilities, equipment and infrastructure to provide R&D support for contract manufacturing and custom biologics development. Release

> ATMI has completed the expansion of its Bloomington, MN, manufacturing facility, the North American hub for production and development of the Integrity single-use technology products. Announcement

Suggested Articles

Dr. Reddy’s says it has been told the FDA will not take regulatory action at its sterile formulations plant in Duvvada, Visakhapatnam.

The end is near for a GlaxoSmithKline OTC plant in Pennsylvania and its 260 employees. In fact, it has a date. 

The FDA is bracing for drug and medical supply shortages in the U.S. as the COVID-19 outbreak from China continues to spread globally.